National Comprehensive Cancer Network



About NCCN

NCCN Updates: Guidelines, Drugs & Biologics, Order Templates

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Antiemesis Have Been Updated and Published as Version 1.2010

Language in "Principles of Emesis Control in the Cancer Patient" has been updated to state "The risk of nausea/vomiting for persons receiving chemotherapy of high and moderate emetic risk lasts for at least 3 days for high and 2 days for moderate after the last dose of chemotherapy. Patients need to be protected throughout the full period of risk."

In "High Emetic Risk Intravenous Chemotherapy – Emesis Prevention," palonosetron has been changed from a Category 2B, preferred designation to a Category 2A designation.
Romidespin was added to the list of agents with low emetic risk. Estramustine was added to the list of oral agents with antiemetic prophylaxis recommended. Pazopanib was added to the list of oral agents with antiemetic agents given only as needed (ie, PRN).

A statement was added in "Principles for Managing Breakthrough Emesis" that "Some patients may require several agents utilizing differing mechanisms of action."

Quick Links


About NCCN| NCCN Member Institutions| Patient Resources| NCCN Foundation| Privacy Policy| Legal Notices| Contact Us

275 Commerce Drive, Suite 300, Fort Washington, PA 19034 • 215.690.0300 • Fax: 215.690.0280
Copyright © 2013 National Comprehensive Cancer Network, All Rights Reserved